Cti Biopharm Corp (CTIC)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
9.09 unch (unch) 06/23/23 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 9.09 unch (unch) -
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2022 | 12-2021 | 12-2020 | 12-2019 | 12-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -92,992 | -97,908 | -52,451 | -40,023 | -29,352 |
| Depreciation Amortization | 1,951 | 526 | 532 | 546 | 593 |
| Accounts receivable | -15,387 | 0 | N/A | 13,674 | -12,389 |
| Accounts payable and accrued liabilities | 7,737 | 5,585 | -4,696 | -7,032 | 923 |
| Other Working Capital | -7,919 | 7,863 | -2,577 | 7,762 | -13,041 |
| Other Operating Activity | 25,416 | -955 | 16,987 | -2,749 | 13,442 |
| Operating Cash Flow | $-81,194 | $-84,889 | $-42,205 | $-27,822 | $-39,824 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -48,853 | 12,000 | -9,600 | 28,132 | -30,457 |
| PPE Investments | N/A | N/A | -17 | N/A | -33 |
| Other Investing Activity | -25,000 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | $-73,853 | $12,000 | $-9,617 | $28,132 | $-30,490 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | -6,329 | -5,333 | -5,608 | -444 |
| Common Stock Issued | 6,366 | 408 | N/A | 1 | 64,170 |
| Common Stock Repurchased | N/A | N/A | 140 | N/A | 54 |
| Other Financing Activity | 113,655 | 103,862 | 66,265 | 0 | -289 |
| Financing Cash Flow | $120,021 | $97,941 | $61,072 | $-5,607 | $63,491 |
| Exchange Rate Effect | N/A | N/A | N/A | 2 | 44 |
| Beginning Cash Position | 65,446 | 40,394 | 31,144 | 36,439 | 43,218 |
| End Cash Position | 30,420 | 65,446 | 40,394 | 31,144 | 36,439 |
| Net Cash Flow | $-35,026 | $25,052 | $9,250 | $-5,295 | $-6,779 |
| Free Cash Flow | |||||
| Operating Cash Flow | -81,194 | -84,889 | -42,205 | -27,822 | -39,824 |
| Capital Expenditure | N/A | N/A | -17 | 0 | -33 |
| Free Cash Flow | -81,194 | -84,889 | -42,222 | -27,822 | -39,857 |